{
  "id": "HERDOO2_Rule_for_Discontinuing_Anticoagulation_in_Unprovoked_VTE.v1",
  "gdl_version": "2.0",
  "concept": "gt0001",
  "language": {
    "original_language": "ISO_639-1::en"
  },
  "description": {
    "original_author": {
      "date": "2020-04-24",
      "name": "Jack Msonkho",
      "organisation": "Cambio CDS",
      "email": "models@cambiocds.com"
    },
    "other_contributors": [
      "Daniel Keszthelyi"
    ],
    "lifecycle_state": "Author draft",
    "details": {
      "en": {
        "id": "en",
        "purpose": "Identifies low-risk women who can safely discontinue VTE treatment.",
        "keywords": [
          "Anticoagulation",
          "Venous thromboembolysm"
        ],
        "use": "The HERDOO2 Rule can identify patients who have very low risk of recurrent VTE and can therefore safely stop anticoagulation in the short term.\n\nUse for women ≥18 years old with unprovoked VTE.\n\nInclusion criteria in the original study was:\n- Patients diagnosed 5–7 months before enrollment.\n- On heparin or low molecular weight heparin (LMWH) for ≥5 days and oral anticoagulation for 5–7 months after the event.\n- Without recurrent VTE during the treatment period.\n- Noncompressible segment on compression ultrasound of popliteal (or more proximal) leg vein, high-probability V/Q scan, or segmental (or larger) artery filling defect on spiral CT.\n\n\nExclusion criteria:\n- Leg fracture.\n- Lower-extremity plaster cast.\n- Immobilization for >3 days.\n- General anesthetic <3 months before index event.\n- Cancer diagnosis within 5 years.\n",
        "misuse": "Do not use in patients with any of the following at the time of VTE diagnosis: leg fracture, lower-extremity plaster cast, immobilization >3 days, general anesthesia <3 months before, or cancer diagnosis within 5 years.",
        "copyright": "@Cambio CDS"
      }
    },
    "other_details": {
      "references": "Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ. 2008;179(5):417-26.\n\nValidation\nRodger MA, Le gal G, Anderson DR, et al. Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study. BMJ. 2017;356:j1065.\n\n"
    }
  },
  "definition": {
    "data_bindings": {
      "gt0002": {
        "id": "gt0002",
        "model_id": "openEHR-EHR-OBSERVATION.herdoo2_rule_for_discontinuing_anticoagulation_in_unprovoked_vte.v0",
        "template_id": "openEHR-EHR-OBSERVATION.herdoo2_rule_for_discontinuing_anticoagulation_in_unprovoked_vte.v0",
        "type": "INPUT",
        "elements": {
          "gt0003": {
            "id": "gt0003",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0004]"
          },
          "gt0004": {
            "id": "gt0004",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0007]"
          },
          "gt0005": {
            "id": "gt0005",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0013]"
          },
          "gt0006": {
            "id": "gt0006",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0010]"
          }
        }
      },
      "gt0009": {
        "id": "gt0009",
        "model_id": "openEHR-EHR-OBSERVATION.herdoo2_rule_for_discontinuing_anticoagulation_in_unprovoked_vte.v0",
        "template_id": "openEHR-EHR-OBSERVATION.herdoo2_rule_for_discontinuing_anticoagulation_in_unprovoked_vte.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0010": {
            "id": "gt0010",
            "path": "/data[at0001]/events[at0002]/data[at0003]/items[at0016]"
          }
        }
      },
      "gt0014": {
        "id": "gt0014",
        "model_id": "openEHR-EHR-EVALUATION.herdoo2_rule_for_discontinuing_anticoagulation_in_unprovoked_vte.v0",
        "template_id": "openEHR-EHR-EVALUATION.herdoo2_rule_for_discontinuing_anticoagulation_in_unprovoked_vte.v0",
        "type": "OUTPUT",
        "elements": {
          "gt0015": {
            "id": "gt0015",
            "path": "/data[at0001]/items[at0005]"
          },
          "gt0016": {
            "id": "gt0016",
            "path": "/data[at0001]/items[at0002]"
          }
        }
      }
    },
    "rules": {
      "gt0011": {
        "id": "gt0011",
        "priority": 3,
        "when": [
          "$gt0003|Post-thrombotic signs|!=null",
          "$gt0004|D-dimer level|!=null",
          "$gt0005|Age, years|!=null",
          "$gt0006|BMI, kg/m²|!=null"
        ],
        "then": [
          "$gt0010|Total Score|.magnitude=$gt0003.value+$gt0004.value+$gt0005.value+$gt0006.value"
        ]
      },
      "gt0019": {
        "id": "gt0019",
        "priority": 2,
        "when": [
          "$gt0010|Total Score|<=1"
        ],
        "then": [
          "$gt0016|Risk Group|=0|local::at0003|Low|",
          "$gt0015|VTE|=0|local::at0006|3%|"
        ]
      },
      "gt0021": {
        "id": "gt0021",
        "priority": 1,
        "when": [
          "$gt0010|Total Score|>1"
        ],
        "then": [
          "$gt0016|Risk Group|=1|local::at0004|Not Low|",
          "$gt0015|VTE|=1|local::at0007|7.4%|"
        ]
      }
    }
  },
  "ontology": {
    "term_definitions": {
      "en": {
        "id": "en",
        "terms": {
          "gt0001": {
            "id": "gt0001",
            "text": "HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE",
            "description": "Indefinite anticoagulation is burdensome and associated with bleeding risk. The HERDOO2 Rule for Discontinuing Anticoagulation in Unprovoked VTE Identifies low-risk women who can safely discontinue Venous thromboembolism (VTE) treatment.\n\nThe HERDOO2 Score is calculated by adding the selected points:\nPost-thrombotic signs*\tNo\t\t\tYes\nD-dimer level\t\t\t<250 µg/L\t≥250 µg/L\nBMI, kg/m²\t\t\t<30\t\t\t≥30\nAge, years\t\t\t<65\t\t\t≥65\n*Hyperpigmentation, edema, or redness (either leg)\n\nIt is interpreted as:\n\nHERDOO2\tRisk group\tRisk of recurrent major VTE*\tRecommendation\n\n0-1\t\tLow\t\t\t3.0%\t\t\t\t\t\tCan safely discontinue oral anticoagulation\n\n2-4\t\tNot low\t\t7.4%\t\t\t\t\t\tContinue oral anticoagulation\n\n*Proximal DVT and segmental or greater PE, % per 100 patient years."
          },
          "gt0003": {
            "id": "gt0003",
            "text": "Post-thrombotic signs",
            "description": "*"
          },
          "gt0004": {
            "id": "gt0004",
            "text": "D-dimer level",
            "description": "*"
          },
          "gt0005": {
            "id": "gt0005",
            "text": "Age, years",
            "description": "*"
          },
          "gt0006": {
            "id": "gt0006",
            "text": "BMI, kg/m²",
            "description": "*"
          },
          "gt0008": {
            "id": "gt0008",
            "text": "Risk Group",
            "description": "*"
          },
          "gt0010": {
            "id": "gt0010",
            "text": "Total Score",
            "description": "*"
          },
          "gt0011": {
            "id": "gt0011",
            "text": "Calculate Score"
          },
          "gt0012": {
            "id": "gt0012",
            "text": "Low Risk Group"
          },
          "gt0013": {
            "id": "gt0013",
            "text": "Not Low Risk Group"
          },
          "gt0015": {
            "id": "gt0015",
            "text": "VTE",
            "description": "*"
          },
          "gt0016": {
            "id": "gt0016",
            "text": "Risk Group",
            "description": "*"
          },
          "gt0017": {
            "id": "gt0017",
            "text": "Low VTE"
          },
          "gt0018": {
            "id": "gt0018",
            "text": "High VTE"
          },
          "gt0019": {
            "id": "gt0019",
            "text": "Low Risk"
          },
          "gt0020": {
            "id": "gt0020",
            "text": "Not Low Risk"
          },
          "gt0021": {
            "id": "gt0021",
            "text": "Not Low Risk"
          }
        }
      }
    }
  }
}